Growing CRO Sword Bio is a fast-acting bioanalytical CRO with over 30 years of combined expertise and a growing leadership team, signaling readiness for expanded collaboration on PK, Biomarkers, and immunogenicity assays across preclinical and clinical phases.

GLP/NGLP Flex The ability to operate in both non-GLP and GLP environments suggests opportunities to engage biotech and pharma sponsors seeking flexible, phased regulatory pathways and scalable bioanalytical support as programs mature.

Recent Leadership Key recent hires in Quality Assurance, Scientific Solutions, and Sales & Marketing indicate a push to strengthen compliance, scientific guidance, and commercial reach, creating openings for partners needing robust quality systems and client-focused engagement.

Mid-market Focus With revenue in the 10–25M range and a leaner employee base, Sword Bio presents an attractive mid-market CRO option for mid-to-late stage programs, accelerating timelines without the overhead of larger CROs.

Strategic Fit Specialization in PK, biomarkers, and immunogenicity assays positions Sword Bio as a complementary partner for biotech firms and small to mid-cap pharma seeking specialized bioanalytical support to de-risk clinical development timelines.